Andra AP fonden Has $25.93 Million Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Andra AP fonden raised its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 28.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,320 shares of the company’s stock after purchasing an additional 8,420 shares during the quarter. Andra AP fonden’s holdings in IDEXX Laboratories were worth $25,925,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in IDXX. Empowered Funds LLC lifted its holdings in IDEXX Laboratories by 6.6% during the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after purchasing an additional 95 shares during the last quarter. Sivia Capital Partners LLC acquired a new stake in IDEXX Laboratories during the 2nd quarter valued at $265,000. Jump Financial LLC lifted its holdings in IDEXX Laboratories by 1,006.4% during the 2nd quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock valued at $2,967,000 after purchasing an additional 5,032 shares during the last quarter. Cary Street Partners Financial LLC acquired a new stake in IDEXX Laboratories during the 2nd quarter valued at $164,000. Finally, Sei Investments Co. lifted its holdings in IDEXX Laboratories by 218.7% during the 2nd quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock valued at $64,678,000 after purchasing an additional 82,755 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 0.2%

IDXX stock opened at $557.91 on Friday. The company has a market cap of $44.01 billion, a PE ratio of 41.08, a price-to-earnings-growth ratio of 3.05 and a beta of 1.55. The business has a 50-day simple moving average of $563.14 and a 200 day simple moving average of $628.16. IDEXX Laboratories, Inc. has a 52 week low of $506.91 and a 52 week high of $769.98. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.IDEXX Laboratories’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Stifel Nicolaus cut their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. UBS Group cut their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Citigroup began coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective on the stock. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Finally, Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Seven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.